Life Science Division Executive Director and Head of Research Dr Navid Malik joins DirectorsTalk to discuss ImmuPharma plc – 10 December 2019

Navid provides an overview of the Life Science Division and how long its been following ImmuPharma, explains how he reads into the agreement with Avion, confidence for securing other deals with European partners, more details around the increase in target price from 76p to 100p, key differentiators, key milestones that will increase share price and how the sector in 2020 could benefit the company.